Pharmaceutical products
Makes and sells branded medicines, over-the-counter health products, and supplements under the company’s own labels.
Customers and revenue model
Pyridam Farma Tbk PT
IDX:PYFA
Pyridam Farma Tbk PT
IDX:PYFA
Price:
130
IDR
-2.26%
Market Closed
Market Cap:
Rp1.5T
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Pyridam Farma Tbk PT
IDX:PYFA
|
ID |
|
Odyssey Gold Ltd
F:ODQ
|
AU |
|
C
|
CAC Holdings Corp
F:CB4
|
JP |
|
T
|
Tyranna Resources Ltd
ASX:TYX
|
AU |
|
Mahaka Media Tbk PT
IDX:ABBA
|
ID |
Company Overview
Business Description
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Headquarters
- Indonesia ID
- Employees
- 2 341
- IPO date
- Oct 16, 2001
Pyridam Farma Tbk PT is an Indonesian pharmaceutical company that develops, manufactures, and sells medicines and health products. Its portfolio includes prescription drugs, over-the-counter medicines, supplements, and other healthcare products used by doctors, pharmacies, hospitals, and consumers. In simple terms, it sits in the middle of the drug supply chain: it turns raw ingredients into finished products and brings them to the market under its own brands and business partners.
The company makes money by selling those products through distributors, pharmacies, healthcare facilities, and other channels in Indonesia and related markets. Its customers include medical professionals and institutions that buy branded medicines, as well as retail buyers who purchase consumer health products. Like other drugmakers, it depends on product approvals, manufacturing quality, and steady access to sales channels more than on one single customer or contract.
What makes its business model different is that it combines pharmaceutical manufacturing with brand building and product distribution. That means it can earn revenue both from making medicines for its own labels and from supplying healthcare products that are sold through third-party channels. For investors, it is best understood as a local healthcare company whose role is to produce and market everyday medicines and related products rather than to run hospitals or sell insurance.